Development of Preventive Vaccines for Hepatitis C Virus E1/E2 Protein

Document Type: Review Article

Authors

1 Dept. of Medical Biotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2 Biochemistry of Nutrition Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

3 Molecular Medicine Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

4 Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

10.30699/ijp.13.2.113

Abstract

Hepatitis C virus (HCV) is responsible for a vast majority of liver failure cases. HCV is a kind of blood disease appraised to chronically infect 3% of the worlds’ population causing significant morbidity and mortality. Therefore, a complete knowledge of humoral responses against HCV, resulting antibodies, and virus-receptor and virus-antibody interactions, are essential to design a vaccine. HCV epitopes or full sequence of HCV proteins can induce HCV specific immune responses. In fact, structural proteins are usually the main target of humoral responses and non-structural proteins are usually the main target of cellular responses. Hence, various vaccines based on distinct antigenic combinations are developed to prevent HCV infection and the current study tried to summarize them.

Keywords

Main Subjects